Nikolay A. Nozdrachev

Nikolay A. Nozdrachev

Auto-generated profile, based on publicly available information

Nikolay A. Nozdrachev

Altai State Medical University of the Ministry of Healthcare of the Russian Federation

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 May 2021 in Urology Reports (St. - Petersburg)
Verified
Journal Article
Closed access
PDF file
ANAleksandr I. Neymark
Aleksandr I. Neymark
BNBoris A. Neymark
Boris A. Neymark
NNNikolay A. Nozdrachev
Nikolay A. Nozdrachev
MGMichail Y. Gatkin
Michail Y. Gatkin
YFYulia S. Fursa
Yulia S. Fursa
INTRODUCTION: Phytopreparations are one of the leading medicines used as preoperative preparation and postoperative management in patients with urolithiasis. THE AIM of the study was to evaluate the nephroprotective effect of Renotinex in patients with urolithiasis after extracorporeal shock wave lithotripsy (ESWL). MATERIALS AND METHODS: The study included 86 patients (43 in the main and the comparison group) with urolithiasis with localization of the stone in the renal pelvis without disturbing the outflow of urine. All patients underwent extracorporeal shock wave lithotripsy (ESWL). After ESWL patients in both groups received spasmodic, anti-inflammatory, antibacterial therapy. Patients of the main group additionally received Renotinex 2 capsules 3 times a day for 14 days before and 14 days after surgery. RESULTS: During the observation a more effective discharge of calculus fragments was noted in patients of the main group while taking the phytocomplex Renotinex, as well as less pronounced damage and faster recovery of the renal parenchyma after ESWL according to the level of enzimuria. CONCLUSION: The results of the study indicate the feasibility of prescribing the phytocomplex Renotinex for nephroprotective and lithokinetic therapy in patients after ESWL.

26 October 2020 in Urology Reports (St. - Petersburg)
Verified
Journal Article
Open access
PDF file
ANAleksandr Neymark
Aleksandr Neymark
BNBoris Neymark
Boris Neymark
NNNikolay Nozdrachev
Nikolay Nozdrachev
ADAndrej Davydov
Andrej Davydov
IKIrina Kablova
Irina Kablova
APAnzhelika Plotnikova
Anzhelika Plotnikova
In the study 46 men with impaired fertility and the presence of viscosipathy were included. The patients age ranged from 22 to 45 years, the average duration of infertility in marriage was 3.5 2.4 years. All patients with Longidaza drugs according to the following scheme were treated. First, ten intramuscular injections of Longidaza lyophilisate were performed to prepare a solution of 3000 IU once every five days, then Longidaza suppositories 3000 IU rectally once every three days were prescribed, for a total of 15 suppositories. The total duration of the course of treatment is 90 days. A decrease in sperm viscosity from 2.1 0.05 cm to 0.6 0.07 cm (p 0.05), an increase in total sperm motility (from 32.6 2.9 to 61 3.1%, p 0.05) and the number of sperm with progressive movement (from 22 1.1 to 36.7 2.9 %, p 0.05) after the treatment were revealed. Also, in the course of treatment, the restoration of the antioxidant protection of the ejaculate was noted, as evidenced by an increase in the activity of glutathione peroxidase and superoxide dismutase and a decrease in the content of malon dialdehyde. During the first year after the end of treatment, conception in marriage was registered in 21 (45.7%) patients. The results of the study indicate that a violation of the lipid peroxidation system can lead to both an increase in sperm viscosity and a disruption in the activity of acrosomal enzymes, as a result of which it becomes difficult for spermatozoa to penetrate the ovum. Longidaza is able to increase the hyaluronidase activity of the sperm acrosome, thereby improving the fertilizing ability of the ejaculate.